Cic edizioni internazionali
Il Giornale di Chirurgia

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance

Review, 225 - 235
doi: 10.11138/gchir/2016.37.5.225
Tag this article
Abstract
Enhanced HTML Full text PDF
Conventional therapeutic approaches for advanced prostate cancer - such as androgen deprivation, chemotherapy, radiation - come up often against lack of effectiveness because of possible arising of correlative cancer cell resistance and/or inadequate anti-tumor immune conditions.
Whence the timeliness of resorting to immune-based treatment strategies including either therapeutic vaccination-based active immunotherapy or anti-tumor monoclonal antibody-mediated passive immunotherapy.
Particularly attractive, as for research studies and clinical applications, results to be the cytotoxic T-lymphocyte check point blockade by the use of anti-CTLA-4 and PD-1 monoclonal antibodies, particularly when combined with androgen deprivation therapy or radiation. Unlike afore said immune check point inhibitors, both cell-based (by the use of prostate specific antigen carriers autologous dendritic cells or even whole cancer cells) and recombinant viral vector vaccines are able to induce immune-mediated focused killing of specific antigen-presenting prostate cancer cells. Such vaccines, either used alone or concurrently/sequentially combined with above-mentioned conventional therapies, led to generally reach, in the field of various clinical trials, reasonable results particularly as regards the patient's overall survival. Adoptive trasferred T-cells, as adoptive T-cell passive immunotherapy, and monoclonal antibodies against specific antigen-endowed prostate cancer cells can improve immune micro-environmental conditions. On the basis of a preliminary survey about various immunotherapy strategies, are here also outlined their effects when combined with androgen deprivation therapy or radiation. What's more, as regard the immune-based treatment effectiveness, it has to be pointed out that suitable personalized epigenetic/gene profile-achieved pharmacogenomic approaches to target identified gene aberrations, may lead to overcome – as well as for conventional therapies – possible prostate cancer resistance to immunotherapy.

Vol. XXXVIII (No. 1) 2017 January - February

  1. The non-surgical management for hemorrhoidal disease. A systematic review
    Cocorullo G., Tutino R., Falco N., Licari L., Orlando G., Fontana T., Raspanti C., Salamone G., Scerrino G., Gallo G., Trompetto M., Gulotta G.
    doi: 10.11138/gchir/2017.38.1.005
  2. 23-hour observation endocrine neck surgery: lessons learned from a case series of over 1700 patients
    Raspanti C., Porrello C., Augello G., Dafnomili A., Rotolo G., Randazzo A., Falco N., Fontana T., Tutino R., Gulotta G.
    doi: 10.11138/gchir/2017.38.1.015
  3. Lymph node assessment in colorectal cancer surgery: laparoscopic versus open techniques
    Balducci G., Sederino M.G., Laforgia R., Carbotta G., Minafra M., Delvecchio A., Fedele S., Tromba A., Carbone F., Palasciano N.
    doi: 10.11138/gchir/2017.38.1.023
  4. Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report
    Albano D., Sinagra E., Patti C., Narese D., Agrusa A., Di Buono G., Raimondo D., Midiri M., Lagalla R., Galia M.
    doi: 10.11138/gchir/2017.38.1.027
  5. Deep sternal wound infections: a severe complication after cardiac surgery
    Morgante A., Romeo F.
    doi: 10.11138/gchir/2017.38.1.033
  6. Neoplastic sigmoid-uterine fistula. An exceptional complication of large intestine cancer
    Zanghì G., Leanza V., Vecchio R., D'Agati A., Cordova S., Rinzivillo N.M., Lodato M., Leanza G.
    doi: 10.11138/gchir/2017.38.1.037
  7. Deep SSI after mesh-mediated groin hernia repair: management and outcome in an Emergency Surgery Department
    Salamone G., Licari L., Augello G., Campanella S., Falco N., Tutino R., Cocorullo G., Gullo R., Raspanti C., De Marco P., Porrello C., Profita G., Gulotta G.
    doi: 10.11138/gchir/2017.38.1.041
  8. Agenesis of the internal carotid artery: a family pathology?
    Perla F.M., Carbotta G., Di Nardo D., D'Avanzo M., Colaiacomo M.C., Di Biasi C., Falvo L., Carbotta S., Maturo A., Tartaglia F., Tromba L.
    doi: 10.11138/gchir/2017.38.1.046
  9. Cyanoacrylate sealant compared to fibrin glue in staple line reinforcement during laparoscopic sleeve gastrectomy. Pilot prospective observational study
    Martines G., Digennaro R., De Fazio M., Capuano P.
    doi: 10.11138/gchir/2017.38.1.050
  10. Supergiant fecaloma as manifestation of chronic constipation
    Currò G., Lazzara C., Latteri S., Bartolotta M., Navarra G.
    doi: 10.11138/gchir/2017.38.1.053
Last Viewed articles: la lista degli ultimi x visitati.
  1. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
    Alberti C.
    doi: 10.11138/gchir/2016.37.5.225
credits